Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?-Reference-Cited by-同舟云学术

Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Published:2024-04-27 Issue:9 Volume:8 Page:2130-2132
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Sánchez-Salinas Mario Andrés¹²^ORCID,Miarons Marta³⁴^ORCID,Troconiz Iñaki F.⁵^ORCID,Navarro Víctor⁶^ORCID,Varela Javier³^ORCID,Iacoboni Gloria¹²^ORCID,Barba Pere¹²

Affiliation:

1. 1Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain

2. 2Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain

3. 3Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

4. 4Pharmacy Department, Consorci Hospitalari de Vic, Barcelona, Spain

5. 5Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain

6. 6Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Publisher

American Society of Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/8/9/2130/2224882/blooda_adv-2023-011433-main.pdf

Reference8 articles.

1. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma;Wallen;PLoS One,2009

2. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells;Hirayama;Blood,2019

3. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes;Langenhorst;Blood Adv,2019

4. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy;Fabrizio;Blood Adv,2022

5. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia;Dekker;Blood Adv,2022